April signifies a historic moment as the sitting President declares it National Cancer Prevention & Early Detection Month, emphasizing the vital importance of combating cancer in its early stages for millions of Americans. Timely with this proclamation, an innovative technology stands ready to redefine early cancer detection forever. Developed by Base Molecular Resonance™ Technologies, the patented Base Molecular Resonance™ technology introduces a singular, non-invasive, harmless scan capable of instantly identifying up to 200 types of cancers and other diseases based on their molecular composition. This groundbreaking discovery promises to forever change cancer detection, consigning late-stage diagnoses to the annals of history. With an estimated two million cancer diagnoses projected in the United States alone this year, this breakthrough emerges at a pivotal moment, offering the prospect of saving countless lives from this devastating disease.
Late-stage cancer detection can no longer be ignored
Nearly half of cancer diagnoses occur at advanced stages, making treatment significantly more challenging. Importantly, delays in diagnosis, regardless of their cause, can profoundly impact treatment effectiveness and patient survival rates. A study conducted in 2020 revealed that even a one-month delay in cancer treatment could increase the risk of death by 6% to 13%. Moreover, with each passing month, this risk continues to escalate. For instance, lung cancer is responsible for nearly 20% of cancer-related deaths in the United States. Patients diagnosed early have a five-year survival rate of 56%, whereas in late stages, this rate drops drastically to 5%.
Time is of the essence in detecting and treating cancer
Late cancer diagnoses can occur for various reasons, many rooted in the complexity of detecting certain types of cancer. Some cancers, characterized by slow progression, can quietly advance for years, evading detection until they reach advanced stages. This prolonged latency period, which can span a decade or more, contributes to delayed diagnoses. Moreover, rare cancers may be overlooked due to limited research, resulting in symptoms that oftentimes do not immediately raise concerns among healthcare professionals.
Despite the challenges, certain cancers can be identified through straightforward and sometimes cost-free screening methods. For instance, the CDC’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP) offers free or low-cost breast and cervical cancer screenings to women with limited incomes or lacking insurance coverage. Similarly, colorectal and lung cancer screenings are available to eligible individuals. However, those who do not meet the screening criteria and individuals with long-term asymptomatic cancers, such as lung cancer, require consistent access to primary care for timely diagnosis.
Quantum physics transforms the landscape for survival
This brings us to Base Molecular Resonance™ Technologies, LLC (BMRT), and the discovery of an area of quantum physics that will transform cancer detection. This cutting-edge innovation enables instantaneous detection through a single, non-invasive, harmless scan. BMRT’s multi-decade research journey has given birth to our ability to detect cancers at their earliest stages. November 2022 marked a significant milestone for the company as the technology and system received full patent approval. At present, the device is capable of detecting all elements on the periodic table and up to 200 types of cancers and other diseases.
The significance of this new technology extends far beyond simply a new form of cancer detection—it holds the power to save lives and preserve families. As a cancer survivor who also witnessed my mother’s battle with stage four ovarian cancer—a disease that tragically claimed her life—I am acutely aware of the profound impact early detection with BMR™ could have had. My experience is just one of many. If only my mom had the opportunity to walk into the doctor’s office and undergo a quick screening with BMR™ technology she could have received early and potentially life-saving news in mere seconds. The thought of how many lives could be spared, how many families could be kept whole, is immense. With BMR™ technology, we have the chance to rewrite the narrative of cancer—to transform heartbreak into hope and loss into life.
Robert “Bo” Short
Robert “Bo” Short is CEO & Co-Founder of Base Molecular Resonance™ Technologies.
